Novartis/Schering AG's Vatalanib Efficacy Not CONFIRMed; Filing Delayed Until 2007
This article was originally published in The Pink Sheet Daily
Executive Summary
Colorectal cancer agent fails to meet primary endpoint of central radiology review-assessed progression-free survival in the CONFIRM-1 trial, Novartis says. The company expects data on overall survival for the agent, also known as PTK-ZK, to be available in the second half of 2006.
You may also be interested in...
Novartis/Schering AG Re-Evaluating PTK/ZK Development Due To Low Probability Of Survival Benefit
Firms plan to reconsider NDA submission strategy after interim analysis of CONFIRM-2 trial suggests PTK/ZK 787 is unlikely to yield survival benefit in second-line metastatic colorectal cancer.
Novartis/Schering AG Re-Evaluating PTK/ZK Development Due To Low Probability Of Survival Benefit
Firms plan to reconsider NDA submission strategy after interim analysis of CONFIRM-2 trial suggests PTK/ZK 787 is unlikely to yield survival benefit in second-line metastatic colorectal cancer.
Schering AG Making Oncology A Primary Focus; Dermatology Unit Will Become Separate Entity
Berlex’ German parent says the new focus will help it exploit the potential of a Phase III angiogenesis inhibitor under development with Novartis. Portfolio restructuring includes termination of R&D in cardiovascular and CNS areas, except for multiple sclerosis and Parkinson’s disease.